A Phase II Open-label Multi-center Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2015
At a glance
- Drugs Edotreotide Y-90 (Primary)
- Indications Carcinoid tumour
- Focus Adverse reactions; Therapeutic Use
- Sponsors Molecular Insight Pharmaceuticals
- 25 Nov 2015 Status changed from completed to withdrawn prior to enrolment, as reported by ClinicalTrials.gov record.
- 10 Jul 2008 New trial record.